MX2023004654A - Agonista de receptor de melanocortina-4 amorfo. - Google Patents

Agonista de receptor de melanocortina-4 amorfo.

Info

Publication number
MX2023004654A
MX2023004654A MX2023004654A MX2023004654A MX2023004654A MX 2023004654 A MX2023004654 A MX 2023004654A MX 2023004654 A MX2023004654 A MX 2023004654A MX 2023004654 A MX2023004654 A MX 2023004654A MX 2023004654 A MX2023004654 A MX 2023004654A
Authority
MX
Mexico
Prior art keywords
amorphous
melanocortin
receptor agonist
compound represented
chemical formula
Prior art date
Application number
MX2023004654A
Other languages
English (en)
Inventor
Sang Dae Lee
Sung Won Kim
Ji Yoon Kim
Ho Yeon Lee
Jin Ok Ham
Seul Ah Chun
Jong Won Park
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2023004654A publication Critical patent/MX2023004654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a un compuesto amorfo representado por la fórmula 1, un método para preparar el mismo, y una composición farmacéutica que comprende el mismo. El compuesto amorfo representado por la fórmula 1 de la presente invención se puede caracterizar por patrones XRD, perfiles DSC y/o perfiles TGA.
MX2023004654A 2020-10-29 2021-10-29 Agonista de receptor de melanocortina-4 amorfo. MX2023004654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200142399 2020-10-29
PCT/KR2021/015467 WO2022092908A1 (ko) 2020-10-29 2021-10-29 무정형의 멜라노코르틴-4 수용체 작용제

Publications (1)

Publication Number Publication Date
MX2023004654A true MX2023004654A (es) 2023-05-18

Family

ID=81384115

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004654A MX2023004654A (es) 2020-10-29 2021-10-29 Agonista de receptor de melanocortina-4 amorfo.

Country Status (13)

Country Link
EP (1) EP4219471A4 (es)
JP (1) JP2023548162A (es)
KR (1) KR20220057469A (es)
CN (1) CN116419757A (es)
AU (1) AU2021370071B2 (es)
CA (1) CA3195214A1 (es)
CL (1) CL2023001221A1 (es)
CO (1) CO2023006514A2 (es)
IL (1) IL302425A (es)
MX (1) MX2023004654A (es)
PE (1) PE20231379A1 (es)
WO (1) WO2022092908A1 (es)
ZA (1) ZA202305591B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022139441A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 무정형의 멜라노코르틴 수용체 작용제 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766191B2 (en) * 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
CA2433025A1 (en) * 2001-01-23 2002-08-01 Chaoyu Xie Substituted piperidines/piperazines as melanocortin receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
KR100661118B1 (ko) * 2003-11-12 2006-12-26 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
MX2019009463A (es) 2017-02-08 2019-12-16 Tilray Inc Metodo y aparatos para procesamiento de canabis a traves de energia radiante de baja presion.
MX2021014074A (es) * 2019-11-07 2021-12-10 Lg Chemical Ltd Agonistas de receptor de melanocortina-4.

Also Published As

Publication number Publication date
AU2021370071B2 (en) 2024-01-11
JP2023548162A (ja) 2023-11-15
PE20231379A1 (es) 2023-09-07
EP4219471A1 (en) 2023-08-02
EP4219471A4 (en) 2024-03-13
CN116419757A (zh) 2023-07-11
AU2021370071A1 (en) 2023-06-01
IL302425A (en) 2023-06-01
CL2023001221A1 (es) 2023-11-03
CA3195214A1 (en) 2022-05-05
KR20220057469A (ko) 2022-05-09
ZA202305591B (en) 2024-09-25
WO2022092908A1 (ko) 2022-05-05
CO2023006514A2 (es) 2023-07-31

Similar Documents

Publication Publication Date Title
ZA202305594B (en) Crystalline form i of melanocortin receptor agonist compound, and method for preparing same
ZA202305593B (en) Crystalline form iii of melanocortin receptor agonist compound and method for preparing same
ZA202305590B (en) Crystal form iv of melanocortin receptor agonist compound, and preparation method therefor
ZA202305595B (en) Crystal type ii of melanocortin receptor agonist compound and method for preparing same
EA200600323A1 (ru) γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
ZA202305591B (en) Amorphous melanocortin-4 receptor agonist
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
UA93531C2 (en) Novel hydrogen sulfate salt
MX2010001605A (es) Metodo para producir olefinas fluoradas.
GEP20094576B (en) New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
NZ578697A (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
TW200643053A (en) Organoaluminum precursor compounds
WO2008110281A3 (de) 3,4-disubstituierte phenoxyphenylamidine und deren verwendung als fungizide
ZA202309546B (en) Agrochemical composition of solid state form of pyroxasulfone
MX2017017022A (es) Metodo para la sintesis de derivados de rapamicina.
UA96149C2 (en) Method for producing 4-oxoquinoline compound
MX2023013044A (es) Forma cristalina v del compuesto agonista del receptor de melanocortina y metodo para preparar la misma.
MX2023013042A (es) Forma cristalina vii de un compuesto agonista del receptor de melanocortina, y metodo para preparar la misma.
CY1115409T1 (el) Νεο πολυμορφο του υδροχλωρικου αλατος του (4-υδροξυκαρβαμοϋλ-φαινυλ)καρβαμικου (6-διμεθυλαμινο μεθυλ-2-ναφθαλενυλ)εστερα
MX2023013129A (es) Forma cristalina iv de sales de acidos organicos del compuesto agonista del receptor de melanocortina y metodo de preparacion de este.
WO2006110534A3 (en) A process for preparing a crystalline form of halobetasol propionate
WO2008092928A3 (de) NEUE ß-LACTAM-ANTIBIOTIKA, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG